NIPER JEE 2011: Results Declared

Finally, the much awaited NIPER JEE 2011 results are out!!

You can check the result on:
http://www.niper.ac.in/result2011.htm

The whole PharmaBlockbusters Team congratulates all the students who cleared the exam!! Those who were not qualified, dont worry...There are going to be many opportunities ahead!!

All the best for the future!!
Below is the list of the counselling dates.

20th  July 2011: All category Rank 1 - 500
Rank 1-100	8:00 a.m.
Rank 101-200	11:30 a.m.
Rank 201-300	1:30 p.m.
Rank 301-500	3:30 p.m.
21st  July 2011: All category Rank 500 - 2215
Rank 500-750	8:00 a.m.
Rank 751-1500	11:30 a.m.
Rank 1501-2215	1:30 p.m.
22nd July 2011
SC candidates Rank 2228 to 2938	8:00a.m.
ST candidates upto Rank 2342 to 2890	11:00a.m.
PH candidates Rank 2580 to 3465	12:30 p.m.
KM Rank upto 2215/Sponsored candidates	2:00 p.m.

Documents to be submitted in ORIGINAL (alongwith a set of photocopies of these documents)

1. Matriculation Certificate as a proof of age and correct name.
2. Marks sheet of all the semesters of the qualifying degree.
3. Valid GPAT/GATE/NET Card
4. Admit Card of NIPER-JEE 2011.
5. Certificate of reservation, if applicable
6. Certificate of reservation and certificate of income (showing non-creamy layer status of the OBC candidates as provided in OM No. 36033/3/2004-Estt. (Res) dated 9^th March, 2004 of the Department of Personnel and Training, Ministry of Personnel, Public Grievances and Pension or any subsequent order issued by the Government of India in this regard).
7. Certificate of disability, if applicable.
8. Medical Certificate  [Format provided in Information Brochure at Annexure -1]
9. Sponsorship certificate from the employer in case of Government/ Industry sponsored candidates as per form attached in Information Brochure at Annexure -2 (Date of counselling � 22-07-2011)
10. Documentary proof in support of the NRI status
11. Undertaking from the candidate as per the provisions of anti-ragging verdict by Hon�ble Supreme Court in form given at Annexure 3 in Information Brochure
12. Undertaking to be given by the parents against ragging at Annexure 4 in Information Brochure

Read More

E-Patient Dave: An Ultimate Warrior

Summary:

When Dave deBronkart learned he had a rare and terminal cancer, he turned to a group of fellow patients online and found the medical treatment that saved his life. Now he calls on all patients to talk with one another, know their own health data, and make health care better one e-Patient at a time.

E-patient Dave: On how he defeated cancer through a patient community!!

Here, Dave deBronkart( better known as E-Patient Dave) shares his views of how he was diagnosed with late stage renal cancer, and how he fought the battle against the killer of all diseases.

Odds were stacked against him, with tumors in both lungs, several bones and muscle tissue. The doctors gave him a time of 24 weeks!! Dave, who was always a google fan...just reviewed many articles, and after going through 3 pages of dejection...he found hope on a patients forum, which suggested him to take Interleukin treatment, only 

available in certain specialist hospitals.

He got the name and address of the doctors providing this treatment, which a regular doctor could not have provided..coz they are almost unaware about it!! and we thought we could totally rely on Doctors...!

Well, He received great treatment, and was able to fight through and win the battle over his cancer.  His last treatment was July 23, 2007, and by September it was clear he’d beaten the disease.


Dont you think that's awesome??? All through a patient network...seems we wont be requiring a doctor's expertise in future!!
Does it bring hope for all those still fighting??? Its a Definite YES....


deBronkart is now actively engaged in opening health care information directly to patients on an unprecedented level, thus creating a new dynamic in how information is delivered, accessed and used by the patient.


This Video will definitely Inspire all those who have lost hope, just because a doctor has given them a thumbs down.....!! Dont Worry people, the World is changing,what with our E-patient Dave winning a battle (against all odds) and raising hopes of many patients throughout the world!!
The slogan goes perfectly...as set by Dave:

"LET PATIENTS HELP"

Read More

FDA Inspection In several Indian Manufacturing Plants: A Boost in Exports Expected!!

The US drug regulator has inspected manufacturing plants of at least half a dozen Indian drugmakers in the last few weeks, raising hopes among some of these companies that they will shortly be able to export medicines to the world's largest drug market. 


Several industry executives said teams of inspectors of the US Food and Drugs Administration (FDA) did not find any major deficiency during inspection of facilities of Ranbaxy Laboratories, Orchid Chemicals & Pharmaceuticals, Emcure Pharma, Nectar Lifesciences and Ind Swift Laboratories over the course of the last four weeks.


Senior industry executives said this was the first time that FDA had inspected so many manufacturing units in India during such a short span of time.
An estimated $30-40 billion worth of drugs, including top-selling drugs like Lipitor (Pfizer), Nexium (Astra Zeneca) and Plavix ( Bristol Myers Squibb), will lose patent protect protection in the next 1-2 years. This means generic firms can launch their versions at one-tenth of the price of the original brand, if they have FDA approval. For the US consumer, sale of more generic drugs will result in greater competition and therefore, lower prices. 


Ranbaxy Laboratories, the country's largest drugmaker, stands to benefit the most from a favourable report from the FDA. The US constitutes a fourth of Ranbaxy's total sales and a nod from the FDA will permit the Gurgaon-based firm to sell new drugs in the US from its Indian plants, nearly three years after FDA banned and halted marketing approval of new drugs from its two main plants for data fabrication. Two FDA officials spent about two weeks examining the drugmaker’s new manufacturing facility at Mohali, Punjab and it is learnt that they have not pointed out any major flaw during the examination. 


Several other plants which were inspected are listed below:

COMPANY	PRODUCT	LOCATION
Ranbaxy	Finished dosage	Mohali
Nectar Lifesciences	API	Chandigarh
Ind Swift	API	Chandigarh
Orchid Chemicals	API	Chennai
Emcure Pharma	API	Pune
Mumbai based Firm	API	Ahmedabad

 According to the Pharmaceutical Exports Council of India, US accounts for about a quarter of the country’s  50,000-crore drug market. Despite increased pressure on margins, the US market remains highly profitable and a key growth driver for many Indian companies.


(Source: Economic Times)

Read More